Mazdutide
Dual GLP-1/Glucagon receptor agonist developed in China showing 18%+ weight loss with additional metabolic benefits.
Last updated: May 2026
Category
Weight Loss (GLP-1/Glucagon)
Frequency
Once weekly injection
Research
Phase 3 Clinical TrialsWhat is Mazdutide?
Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in China. It shares the dual-agonist approach of retatrutide but without the GIP component, instead pairing GLP-1 with glucagon agonism, which drives thermogenesis and direct fat oxidation. Browse all weight loss peptide options to compare.
In Phase 3 clinical trials conducted primarily in Chinese and Asian populations, Mazdutide demonstrated approximately 18% body weight reduction over 36 weeks, positioning it between tirzepatide (22.5%) and semaglutide (15%) in terms of efficacy. Given that clinical trial populations were Asian, results may be particularly relevant to Vietnam users.
Mazdutide also shows promise beyond weight loss: trials have demonstrated improvements in NAFLD (fatty liver disease), with significant reductions in liver fat content. This makes it particularly interesting for users with metabolic liver conditions.
How It Works
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, enhance insulin secretion, and slow gastric emptying, the same core mechanism as Semaglutide and the GLP-1 component of Tirzepatide.
Glucagon Agonism: Activates glucagon receptors which directly increase metabolic rate (thermogenesis), stimulate fat oxidation particularly in the liver, and enhance energy expenditure. This is the key differentiator from pure GLP-1 drugs.
Hepatic Fat Reduction: The glucagon component has particular efficacy in reducing liver fat (hepatic triglycerides), making Mazdutide uniquely effective for NAFLD/MAFLD alongside its weight loss properties.
Benefits
- ~18% average body weight reduction in Phase 3 trials
- Significant reduction in liver fat: useful for NAFLD
- Improved insulin sensitivity and HbA1c reduction
- Favorable Asian population trial data (directly relevant)
- Weekly dosing for convenience
- Thermogenic effect from glucagon agonism
- Emerging availability as research peptide in Vietnam
Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 3mg | Once weekly | Weeks 1–4 |
| Titration | 4.5–6mg | Once weekly | Weeks 5–12 |
| Maintenance | 6mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Side Effects
Common
- ⚠Nausea (most common during titration)
- ⚠Decreased appetite
- ⚠Diarrhea
- ⚠Vomiting (resolves with slower titration)
- ⚠Injection site reactions
Rare
- •Elevated liver enzymes (monitor if pre-existing liver disease)
- •Hypoglycemia risk with concurrent diabetes medications
- •Gallbladder issues (associated with rapid weight loss)
- •Pancreatitis (rare, discontinue if severe abdominal pain)
Who Should NOT Use Mazdutide
- ✕Personal or family history of medullary thyroid carcinoma
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of pancreatitis
- ✕Severe hepatic impairment
- ✕Pregnancy or breastfeeding
- ✕Under 18 years old
What to Expect
Starting dose phase. Appetite reduction begins. Nausea may occur but is typically manageable.
Appetite markedly reduced at titration dose. Weight loss accelerates, often 1–1.5kg per week with dietary awareness.
Consistent fat loss continues. The glucagon component produces noticeable thermogenic benefit: users often report feeling warmer and more energetic.
Notes from Ho Chi Minh City
Mazdutide is the GLP-1/glucagon dual agonist that makes the most sense for the Vietnam expat population specifically because the Phase 3 trial data was generated in Asian-population cohorts at the Innovent Biologics development sites in Beijing and Shanghai, which is closer to baseline body composition for HCMC residents than the European-American Mounjaro and Wegovy trial data. The 18 percent body weight reduction at the 6mg weekly maintenance dose is the relevant number, and the glucagon-driven thermogenic effect is real; users report feeling noticeably warmer 24 to 48 hours after the shot, which is meaningful in HCMC heat. The hepatic fat reduction from the glucagon component matters because NAFLD is widespread in middle-aged Vietnamese men. Research-grade Mazdutide in Vietnam runs 1.8 to 2.5 million VND per 5mg vial through cold-chain importers, slightly under tirzepatide pricing.
Sourcing in Vietnam
Mazdutide is approved in China through Innovent Biologics but is not registered with the DAV in Vietnam and is not stocked at Long Châu, Pharmacity, FV Hospital, or Vinmec. Sourcing is research-grade only through cold-chain importers (1.8 to 2.5 million VND per 5mg vial), often shipped from regional suppliers with stock from China. See the supplier list and COA guide before purchasing.
FAQ
Q: Is Mazdutide available in Vietnam?
A: Mazdutide is less widely available than retatrutide or tirzepatide but is emerging in the research peptide market. Check the community-verified supplier list for current Vietnam availability and verify purity with the COA verification guide.
Q: How does Mazdutide compare to Tirzepatide?
A: Tirzepatide combines GLP-1 and GIP, while Mazdutide combines GLP-1 and Glucagon. Tirzepatide generally produces slightly more weight loss (22.5% vs 18%), but Mazdutide may have superior effects on liver fat. Both are weekly injections at similar price points.
Q: Is Mazdutide FDA approved?
A: No, Mazdutide is developed by a Chinese company and has primarily been trialed in China. It is not FDA approved but is available as a research peptide. It shares the same receptor mechanisms as approved drugs (Ozempic, Mounjaro) so the safety profile is relatively well understood.
Where to Get Mazdutide in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- Mazdutide for the treatment of obesity in Chinese adults · Ji L, Jiang H, Bi Y, et al. · New England Journal of Medicine (2024) PMID: 38934438
Phase 3 GLORY-1 trial demonstrating approximately 18 percent weight reduction at 6mg weekly in Chinese adults with obesity.
- Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes · Ji L, Gao L, Jiang H, et al. · Lancet Diabetes and Endocrinology (2023) PMID: 37980920
Phase 2 trial in type 2 diabetes supporting the dual GLP-1/glucagon agonism mechanism for glycemic and weight outcomes.
- IBI362, a long-acting GLP-1 and glucagon receptor dual agonist · Lu W, Chen J, Liu T, et al. · Frontiers in Pharmacology (2022) PMID: 36034885
Pharmacological characterization of mazdutide receptor binding and dual-agonist activity profile.
- Glucagon receptor agonism for the treatment of obesity and metabolic disease · Sanchez-Garrido MA, Brandt SJ, Clemmensen C, et al. · Diabetologia (2017) PMID: 28733904
Mechanistic review of the rationale for combining glucagon agonism with GLP-1 for enhanced weight loss and hepatic fat reduction.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.